GENEREX BIOTECHNOLOGY CORP - FORM 10-Q - EX-32 - EXHIBIT 32 - December 9, 2013

Attached files

file filename
EX-10.8 - EXHIBIT 10.8 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_8.htm
EX-10.6 - EXHIBIT 10.6 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_6.htm
EX-10.7 - EXHIBIT 10.7 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_7.htm
EX-31.1 - EXHIBIT 31.1 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh31_1.htm
EX-10.3 - EXHIBIT 10.3 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_3.htm
EX-10.4 - EXHIBIT 10.4 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_4.htm
EX-31.2 - EXHIBIT 31.2 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh31_2.htm
EX-10.1 - EXHIBIT 10.1 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_1.htm
EX-10.5 - EXHIBIT 10.5 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_5.htm
EXCEL - IDEA: XBRL DOCUMENT - GENEREX BIOTECHNOLOGY CORPFinancial_Report.xls
10-Q - FORM 10-Q - GENEREX BIOTECHNOLOGY CORPgnbt112013form10q.htm
EX-10.9 - EXHIBIT 10.9 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_9.htm
EX-10.2 - EXHIBIT 10.2 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_2.htm
EX-10.14 - EXHIBIT 10.14 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_14.htm
EX-10.12 - EXHIBIT 10.12 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_12.htm
EX-10.11 - EXHIBIT 10.11 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_11.htm
EX-10.13 - EXHIBIT 10.13 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_13.htm
EX-10.10 - EXHIBIT 10.10 - GENEREX BIOTECHNOLOGY CORPgnbt112013exh10_10.htm

Exhibit 32

 

CERTIFICATIONS

 

Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. ss. 1350, as adopted), Mark A. Fletcher, Chief Executive Officer and President of Generex Biotechnology Corporation (the "Company"), and Stephen Fellows, Acting Chief Financial Officer of the Company, each hereby certifies that, to the best of their knowledge:

 

1. The Company's Quarterly Report on Form 10-Q for the period ended October 31, 2013 to which this Certification is attached as Exhibit 32 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the end of the period covered by the Report.

 

DATE: December 9, 2013   By: /s/ Mark A. Fletcher
    Mark A. Fletcher
    President & Chief Executive Officer
    (Principal Executive Officer)

 

 

 

DATE: December 9, 2013   By: /s/ Stephen Fellows
    Stephen Fellows
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

 

Stock widget

Investing forum

GENEREX BIOTECHNOLOGY CORP Reports

Also read